白细胞介素-12对抗原特异性CD8反应的剂量依赖性和时间依赖性效应。
Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.
作者信息
Lee K, Overwijk W W, O'Toole M, Swiniarski H, Restifo N P, Dorner A J, Wolf S F, Sturmhoefel K
机构信息
Genetics Institute, Andover, MA 01810, USA.
出版信息
J Interferon Cytokine Res. 2000 Jun;20(6):589-96. doi: 10.1089/10799900050044787.
Abstract
Interleukin-12 (IL-12) has been shown to play a central role in the innate and acquired immune responses. Its activities include enhancement of natural killer (NK) and cytotoxic T lymphocyte (CTL) activity and promotion of CD4 Th1 cell development. It has also been shown to provide potent activity as a vaccine adjuvant in generating antibody and T cell responses. We have investigated the efficacy of IL-12 protein in promoting CD8 T cell responses when it is used as an adjuvant for immunization. Studies using, as antigen, cDNA from an autologous antigen (P1A) as well as studies of responses to vaccinia virus-delivered self (gp100) and non-self (beta-galactosidase) antigens show that the dose and schedule of IL-12 administration can significantly affect adjuvant activity, leading to enhancement or suppression of antigen-specific responses.
摘要
白细胞介素-12（IL-12）已被证明在先天性和获得性免疫反应中起核心作用。其活性包括增强自然杀伤（NK）细胞和细胞毒性T淋巴细胞（CTL）的活性，以及促进CD4 Th1细胞的发育。还已证明它作为疫苗佐剂在产生抗体和T细胞反应方面具有强大活性。我们研究了IL-12蛋白用作免疫佐剂时促进CD8 T细胞反应的功效。使用来自自体抗原（P1A）的cDNA作为抗原的研究，以及对痘苗病毒递送的自身（gp100）和非自身（β-半乳糖苷酶）抗原反应的研究表明，IL-12的给药剂量和方案可显著影响佐剂活性，导致抗原特异性反应增强或抑制。
相似文献
1
Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.
J Interferon Cytokine Res. 2000 Jun;20(6):589-96. doi: 10.1089/10799900050044787.
2
Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
J Immunol. 2003 Nov 15;171(10):5172-9. doi: 10.4049/jimmunol.171.10.5172.
3
Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
Eur Cytokine Netw. 1999 Jun;10(2):181-90.
4
Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
Immunology. 2009 Sep;128(1 Suppl):e707-17. doi: 10.1111/j.1365-2567.2009.03068.x. Epub 2009 Feb 9.
5
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
Int Immunol. 2001 May;13(5):625-32. doi: 10.1093/intimm/13.5.625.
6
Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Int J Cancer. 1999 Nov 12;83(4):532-40. doi: 10.1002/(sici)1097-0215(19991112)83:4<532::aid-ijc16>3.0.co;2-k.
7
Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
J Mol Med (Berl). 2003 Sep;81(9):585-96. doi: 10.1007/s00109-003-0472-5. Epub 2003 Aug 21.
8
Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Cancer Biother Radiopharm. 2010 Feb;25(1):21-8. doi: 10.1089/cbr.2009.0714.
9
10
Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice.
Vaccine. 2001 Oct 12;20(1-2):170-80. doi: 10.1016/s0264-410x(01)00252-3.
引用本文的文献
1
Harnessing innate immune pathways for therapeutic advancement in cancer.
Signal Transduct Target Ther. 2024 Mar 25;9(1):68. doi: 10.1038/s41392-024-01765-9.
2
Feline Infectious Peritonitis as a Systemic Inflammatory Disease: Contribution of Liver and Heart to the Pathogenesis.
Viruses. 2019 Dec 10;11(12):1144. doi: 10.3390/v11121144.
3
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
PLoS One. 2018 Sep 20;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018.
4
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 T-Cell Responses by Interleukin-12 Plasmid DNA.
Clin Vaccine Immunol. 2017 Nov 6;24(11). doi: 10.1128/CVI.00263-17. Print 2017 Nov.
5
A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.
PLoS One. 2014 Sep 12;9(9):e106597. doi: 10.1371/journal.pone.0106597. eCollection 2014.
6
IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques.
Hum Vaccin Immunother. 2012 Nov 1;8(11):1620-9. doi: 10.4161/hv.21407. Epub 2012 Aug 16.
7
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.
Clin Exp Immunol. 2004 Feb;135(2):322-9. doi: 10.1111/j.1365-2249.2004.02360.x.
本文引用的文献
1
IL-12-Dependent enhancement of CTL response to weak class I-restricted peptide immunogens requires coimmunization with T helper cell immunogens.
Clin Immunol. 2000 Mar;94(3):200-11. doi: 10.1006/clim.2000.4836.
2
A CTL assay requiring only 150 microliter of mouse blood.
J Immunol Methods. 2000 Jan 13;233(1-2):1-11. doi: 10.1016/s0022-1759(99)00186-6.
3
Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect.
J Exp Med. 1998 Nov 2;188(9):1603-10. doi: 10.1084/jem.188.9.1603.
4
Interleukin-12: a cytokine at the interface of inflammation and immunity.
Adv Immunol. 1998;70:83-243. doi: 10.1016/s0065-2776(08)60387-9.
5
The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor.
J Immunol. 1998 Jul 15;161(2):927-32.
6
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Clin Cancer Res. 1998 May;4(5):1183-91.
7
Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: cellular and cytokine-mediated effector mechanisms.
Eur J Immunol. 1997 Dec;27(12):3438-46. doi: 10.1002/eji.1830271244.
8
Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.
Cancer Res. 1998 Feb 1;58(3):491-9.
9
IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response.
J Immunol. 1996 Feb 1;156(3):887-94.
10
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
J Immunol. 1996 Feb 1;156(3):1095-100.
Zotero 插件